The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

(2017) Elizabeth M Swisher et al.   LANCET ONCOLOGY

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer

(2016) M. Moschetta et al.   ANNALS OF ONCOLOGY

Interplay between Fanconi anemia and homologous recombination pathways in genome integrity

(2016) Johanna Michl et al.   EMBO JOURNAL

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer

(2014) J. L. Meisel et al.   ANNALS OF ONCOLOGY

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) J. A. Ledermann et al.   ANNALS OF ONCOLOGY

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

(2013) Kathryn P. Pennington et al.   CLINICAL CANCER RESEARCH

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas

(2012) Karuna Garg et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art

(2012) Mike De Vos et al.   BIOCHEMICAL PHARMACOLOGY

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Poly (ADP-ribose) polymerase inhibitors

(2012) Elena S. Ratner et al.   CURRENT OPINION IN ONCOLOGY

Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer

(2012) Kelly L. Bolton   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

(2011) Thomas Helleday   Molecular Oncology

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

(2011) T. Walsh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer

(2011) Johanne I. Weberpals et al.   Cancer Genetics

BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark

(2008) M. Soegaard et al.   CLINICAL CANCER RESEARCH